Home › Clinical Guideline Hubs › Section 11: Gastrointestinal & Surgical › Chapter 11.2
Chapter 11.2 · Section 11: Gastrointestinal & Surgical

Intestinal Failure and Intestinal Rehabilitation

Recognition of neonatal intestinal failure, risk stratification, parenteral and enteral nutrition strategy, IFALD prevention, output replacement, mucous fistula refeeding, micronutrient surveillance, and home-PN discharge planning
Intestinal Rehabilitation Short Bowel Syndrome PN & IFALD Output Replacement Home PN Planning Baylor Ed. 33 cross-checked Sept 2026
Sources: Baylor 2025–2026 (Section 6.2, backbone) · Belize 2018–2021 · West Midlands 2025–2028 (feeding-tube/MDT safety context) · ASPEN neonatal nutrition · NASPGHAN/ESPGHAN cholestasis guidance. Original Neonatology Academy synthesis. Not a substitute for local nutrition, central-line, lipid-emulsion, cholestasis, or home-PN policy. Doses, targets, and thresholds must be verified locally.

Core Bedside Message

Intestinal failure is a high-risk state — plan early, multidisciplinary
  • Neonatal intestinal failure is not simply “poor feeding”; it is a high-risk state of malabsorption, fluid/electrolyte loss, growth failure, central-line dependence, and intestinal failure-associated liver disease (IFALD).
  • Management should begin early with a multidisciplinary intestinal rehabilitation plan, even before the infant is ready for full enteral nutrition.
  • The main modifiable levers: human milk, careful parenteral nutrition, prevention of catheter infection, sodium surveillance, controlled advancement of feeds, ostomy-output replacement, and timely family preparation.

1. Scope and Purpose

  • Applies to preterm and term neonates with anticipated or established intestinal failure after NEC, spontaneous intestinal perforation, volvulus, atresia, gastroschisis, omphalocele, dysmotility, bowel resection, ostomy creation, or prolonged parenteral nutrition dependence.
  • Focuses on NICU bedside recognition, early intestinal rehabilitation, nutrition strategy, monitoring, ostomy/mucous fistula care, IFALD prevention, discharge planning, and when to escalate to gastroenterology, surgery, nutrition, pharmacy, hematology, or transplant teams.
  • This chapter complements local nutrition, central-line, surgical, infection-control, cholestasis, lipid-emulsion, and home-PN policies.

2. Definitions and Clinical Framing

TermPractical DefinitionWhy It Matters
Intestinal failure (IF) Inability of the intestine to absorb enough fluid, electrolytes, macronutrients, and micronutrients to sustain growth and hydration without prolonged parenteral nutrition. Creates risk for central-line infection, thrombosis, IFALD, micronutrient deficiency, oral aversion, and delayed growth.
Short bowel syndrome (SBS) Functional intestinal failure after significant bowel loss; Baylor defines SBS as residual bowel length <60 cm, and ultra-short bowel as <30 cm. Residual bowel length, ileocecal valve status, colon continuity, and ostomy level strongly influence enteral autonomy. For scale: normal bowel length in a term infant is about 200–250 cm, and roughly half that below 30 weeks' gestation. Survival is now 95–100% regardless of residual length with multidisciplinary care, newer lipid emulsions and infection control — length predicts enteral autonomy, not survival.
Enteral autonomy Ability to grow and hydrate without parenteral nutrition. This is the central long-term goal; it may occur after discharge in severe IF. Baylor's outcome figures: with residual bowel above 30 cm, 70–95% achieve enteral autonomy by 4–14 months; below 30 cm, only 50% do, by a median follow-up of 18–30 months.
IFALD Conjugated/direct bilirubin elevation in an infant dependent on PN after other causes are excluded. Major preventable or modifiable complication; risk rises with prematurity, sepsis, lack of enteral feeds, surgery, bacterial overgrowth, NEC/SIP, and prolonged PN.
Intestinal rehabilitation Coordinated medical, nutritional, surgical, developmental, and family-centered plan to promote adaptation and safe transition from PN to enteral nutrition. Best outcomes require early multidisciplinary planning rather than sequential crisis management.

3. Early Risk Stratification: Who Needs an Intestinal Rehabilitation Plan?

Risk GroupTypical TriggersImmediate Action
High risk SBS <60 cm, ultra-short bowel <30 cm, surgical NEC, complex gastroschisis, large omphalocele, intestinal atresia, PN dependence >4 weeks, repeated failed feeding advances with PN dependence, IFALD with PN dependence. Notify/consult intestinal rehabilitation, pediatric surgery, nutrition, pharmacy, and gastroenterology early. Protect central access and begin IFALD prevention from the first PN order.
Moderate risk Residual bowel >60 cm but ostomy present, simple gastroschisis, malrotation/volvulus, SIP, bowel resection of any length, previous feeding intolerance, anticipated PN >2 weeks. Create a feeding-advance and output-replacement plan. Track weight, electrolytes, sodium status, ostomy output, and growth velocity.
Lower risk but needs surveillance Medical NEC without resection, brief PN dependence, growth failure after full fortified feeds, prolonged NPO, or persistent high Replogle/gastric output. Avoid delayed recognition. If growth or electrolytes worsen, escalate and reassess for evolving intestinal failure.
Urgent escalation triggers
  • Ostomy or Replogle output >20 mL/kg/day, rising output trend, oliguria, hyponatremia, metabolic acidosis, weight loss, or poor growth despite adequate calories.
  • Conjugated/direct bilirubin rising or ≥2 mg/dL while PN dependent, recurrent central-line infection, thrombosis, persistent thrombocytopenia, or inability to advance feeds.
  • Abdominal distension, bilious emesis, fixed loops, worsening lactate/acidosis, or concern for stricture, obstruction, recurrent NEC, or anastomotic complication.

4. Initial Stabilization and PN Strategy

  • Place reliable central access for PN in infants with abdominal wall defects, major bowel defects, stage 2 or higher NEC, intestinal perforation, or significant growth failure on full fortified feeds. Use the least risky durable line strategy; reserve tunneled or surgically placed access for long-term PN or failed peripheral PICC access.
  • Start PN promptly once prolonged inadequate enteral nutrition is expected. Target approximately 90–100 kcal/kg/day and protein 3.5–4 g/kg/day in preterm infants or 2–3 g/kg/day in term infants, adjusting to growth, fluid restriction, organ function, and metabolic tolerance.
  • Use a lipid strategy that balances essential fatty acid delivery, growth, triglyceride tolerance, and IFALD prevention. Multicomponent lipid emulsions such as SMOFlipid are often preferred for infants with IF risk; fish-oil lipid rescue or modification should follow local lipid and cholestasis policy.
  • Prevent IFALD by combining early enteral stimulation, human milk exposure, avoidance of unnecessary fasting, meticulous line care, prompt treatment of sepsis, minimization of inflammation, and careful lipid/trace-element monitoring.

5. Enteral Nutrition: Start Early, Advance Deliberately

StepSevere Feeding-Difficulty PathwayModerate Feeding-Difficulty PathwayBedside Monitoring
Patient profile Residual bowel <60 cm, complicated gastroschisis, very proximal ostomy, repeated intolerance, likely home PN. Residual bowel >60 cm, simple gastroschisis, previous intolerance but likely full EN before discharge. Define pathway at multidisciplinary rounds and revise as bowel function evolves.
Start feeds When bowel function returns and output is stable, start 5–10 mL/kg/day. Start 10–20 mL/kg/day when medically feasible. Prefer mother’s own milk; donor milk may be used for preterm infants when mother’s milk is unavailable. Elemental formula may be considered for term or >35 weeks PMA infants with malabsorption/intolerance when human milk is not available.
Advance feeds Advance 5–10 mL/kg once or twice weekly as tolerated. Advance 10 mL/kg 3–4 times/week or 20 mL/kg 2–3 times/week as tolerated. Monitor emesis, gastric/Replogle output, ostomy output, stool pattern, abdominal exam, acidosis, sodium status, weight gain, and oral skills.
If intolerance occurs Return to prior tolerated volume; consider continuous feeds, prolonged infusion, partial PN, obstruction evaluation, dysmotility, or bacterial overgrowth. Same principles; avoid repeated aggressive advances after objective intolerance. Do not interpret isolated residuals alone as NEC or failure; use the whole clinical picture.
Fortification Individualized; often considered around EN 80 mL/kg/day to support PN weaning and growth. Same; choose fortifier/formula according to gestation, human milk availability, osmolality, malabsorption, and team consensus. Avoid high osmolality escalation without clear growth need and team discussion.

6. Monitoring Bundle for Intestinal Failure

DomainWhat to MonitorActionable Interpretation
Daily bedside Weight trend, intake/output, urine output, Replogle output, ostomy output, stool/rectal output, abdominal exam, emesis, perfusion, respiratory support, pain, feeding cues. Do not wait for severe biochemical derangement before replacing losses or slowing feeds. Growth velocity and sodium balance are often early signals.
Weekly labs while on PN Electrolytes, BUN, creatinine, glucose, conjugated/direct bilirubin, triglycerides. Increase frequency with high GI output, renal dysfunction, lipid intolerance, sepsis, or rapid PN/EN changes.
Every 2 weeks or clinically indicated ALT, AST, GGT, alkaline phosphatase, calcium, phosphorus, magnesium, hemoglobin/hematocrit. Screens IFALD, metabolic bone risk, anemia, and mineral deficiency; adjust PN and enteral supplements.
Every 4 weeks or when feasible Zinc, copper, selenium, CBC, iron studies; consider fat-soluble vitamins when enteral intake increases or cholestasis persists. Delay only when blood volume is limiting; transferred infants with established IF should have baseline micronutrient review.
Growth failure work-up Urine sodium, serum sodium, acid-base status, stool/ostomy losses, caloric intake, protein intake, inflammation, CLABSI, and malabsorption. Low sodium stores can cause poor growth despite apparently adequate calories. Replace sodium losses and monitor response.

7. Replogle/Ostomy Output and Replacement Fluids

Practical principle
  • Use 0.9% normal saline as the default replacement fluid for combined Replogle and ostomy losses unless the multidisciplinary team chooses otherwise.
  • When combined output exceeds 20 mL/kg/day, replace losses and increase reassessment frequency as output rises.
  • Adjust PN electrolytes rather than routinely adding electrolyte additives to replacement fluids; consider 0.45% NS only in selected hypernatremic situations with close monitoring.
Combined Replogle + Ostomy OutputReplacement ApproachReassessmentLabs
<20 mL/kg/day No routine replacement; continue routine intake/output review. Every 24 h Routine
20–30 mL/kg/day Replace 0.5 mL 0.9% NS for each 1 mL output over 12–24 h. Every 12–24 h Routine or more often if unstable
30–40 mL/kg/day Replace 0.5 mL 0.9% NS for each 1 mL output over 12 h. Every 12 h Daily electrolytes
>40 mL/kg/day Replace 0.5 mL 0.9% NS for each 1 mL output over 4 h; consider 1:1 replacement if very high output, oliguria, acidosis, or sodium derangement. Every 4 h Daily or more frequent electrolytes

8. Ostomy Feeding, Mucous Fistula Refeeding, and Bowel Adaptation

  • For infants with an ostomy and mucous fistula, consider whether enteral autonomy before re-anastomosis is achievable. This may reduce PN days and cholestasis risk but requires close growth, output, and safety monitoring.
  • Potential candidates include infants 0–12 months old, weight at least 1000 g, with jejunostomy or ileostomy, a mucous fistula, and some enteral/oral feeds already tolerated.
  • Before starting mucous fistula refeeding, confirm distal bowel patency with contrast study and agree on catheter type/depth, frequency, volume, nursing workflow, contamination prevention, and stopping criteria.
  • A common bedside method is to collect ostomy output every 3–4 hours and refeed into the mucous fistula over 1–2 hours using a syringe pump, aiming toward 1:1 refeeding as tolerated. Baylor Ed. 33 specifies inserting and securing the feeding tube 4–5 cm into the mucous fistula, and notes that replacement fluids for losses are not indicated once mucous fistula refeeding is running.
  • Monitor rectal stool output, diarrhea, abdominal distension, skin breakdown, catheter displacement, perforation risk, growth, electrolytes, and signs of feeding intolerance.

9. Bacterial Overgrowth and Dysmotility

ConcernCluesManagement Approach
Small intestinal bacterial overgrowth Worsening feeding intolerance, distension, stool change, high output, mucosal bleeding, cholestasis flare, D-lactic acidosis, unexplained systemic instability. Discuss with intestinal rehabilitation before treatment. Some protocols use enteral/oral metronidazole 10 mg/kg/dose twice daily for one week each month when feeding; avoid routine use while NPO unless specifically indicated.
Dysmotility / obstruction Persistent intolerance despite feed reduction, bilious output, distension, failure to pass stool, recurrent acidosis, fixed radiographic loops, or inability to initiate EN. Hold/step back feeds, decompress, obtain surgical input, and consider contrast studies to distinguish dysmotility, stricture, obstruction, or recurrent disease.
Oral aversion risk Long NPO periods, prolonged intubation, repeated painful oral stimulation, reflux/retching, inability to practice oral skills. Use cue-based positive oral experiences, non-nutritive sucking when safe, milk drops/oral care per local protocol, OT/SLP involvement, and early family participation.

10. Micronutrients, Iron, and Medication Safety

  • Infants on prolonged PN are at risk for deficiencies of iron, zinc, copper, selenium, fat-soluble vitamins, calcium, phosphorus, magnesium, sodium, and essential fatty acids.
  • Iron is not routinely supplied in PN. Infants receiving PN for more than six weeks, especially with minimal enteral intake, require an iron-deficiency surveillance and replacement plan; IV iron may be needed with hematology/intestinal rehabilitation input.
  • Avoid routine sucrose oral solution for painful procedures in infants with significant intestinal failure when there is concern for excessive osmotic load; use the unit pain guideline and non-enteral comfort strategies when appropriate.
  • Review all medications for osmolality, sorbitol content, enteral absorption, hepatic metabolism, and contribution to diarrhea or feeding intolerance.

11. Discharge Planning for Home PN or Complex Enteral Nutrition

Start discharge planning early
  • If home PN is possible, begin planning at least 4–6 weeks before expected discharge.
  • The discharge plan should cover durable central access, PN cycling, line-care competency, emergency fever/line pathway, medication storage, pump use, nutrition prescriptions, laboratory schedule, home nursing, supply delivery, caregiver simulation, and follow-up appointments.
  • PN cycling may be used to promote development and prepare for discharge; typical cycling may include approximately 4 hours off PN/lipid daily, coordinated with pharmacy and line-safety teams.
Readiness DomainMinimum ExpectationDo Not Discharge Until…
Clinical stability Stable cardiorespiratory status, temperature, hydration, urine output, and weight trend. The infant has unresolved high output, electrolyte instability, sepsis concern, or escalating respiratory/hemodynamic support.
Nutrition prescription Home PN/EN plan finalized with calories, protein, fluids, sodium, trace elements, lipids, cycling schedule, and contingency plan. There is ongoing intolerance or unclear response to the current regimen.
Line safety Caregivers demonstrate sterile line access, flushing/locking, pump use, dressing awareness, and fever pathway. Caregivers cannot perform skills or do not have emergency supplies/contact plan.
Labs / follow-up Written lab schedule and appointments with neonatology, GI/intestinal rehab, surgery, nutrition, pharmacy/home infusion, and primary care. Results cannot be reviewed promptly or there is no ownership of abnormal lab response.
Family readiness Parents understand output measurement, dehydration signs, stool/ostomy changes, feeding plan, when to call, and when to go to ED. Caregivers are not confident or have not completed teach-back/simulation.

12. Source Differences and How This Chapter Resolves Them

SourceMain ContributionHow Integrated Here
Baylor 2025–2026 Dedicated intestinal failure chapter with risk stratification, PN targets, enteral advancement, lab surveillance, urine sodium, bacterial overgrowth, output replacement, mucous fistula refeeding, iron, and discharge coordination. Used as the backbone for this chapter and converted into a bedside algorithmic format.
Belize 2018–2021 Provides neonatal PN principles, energy/protein expectations, NEC recovery/refeeding principles, and post-NEC complications such as short bowel syndrome, PN-associated liver disease, malabsorption, and micronutrient needs. Used to reinforce practical nutrition and post-NEC recovery points.
West Midlands 2025–2028 No dedicated intestinal failure chapter identified in the extracted material; contains relevant neonatal safety guidance on feeding-tube placement and multidisciplinary feeding practice. Applied only as general safety context when enteral tubes are used; intestinal rehabilitation details come primarily from Baylor and neonatal nutrition literature.

13. Bedside Algorithm: First 72 Hours After IF Is Suspected

Six-step pathway
  1. Diagnose the risk state: identify bowel anatomy, residual length if known, ostomy level, mucous fistula, ileocecal valve/colon status, surgical history, current output, and reason for PN dependence.
  2. Stabilize: decompress as indicated, secure central access, begin PN, replace losses, correct acid-base/electrolytes, protect perfusion, and treat infection or obstruction concerns.
  3. Call the team early: neonatology, pediatric surgery, nutrition, pharmacy, gastroenterology/intestinal rehabilitation, nursing, OT/SLP, social work, and lactation.
  4. Start gut stimulation when safe: use mother’s milk first, donor human milk for eligible preterm infants when needed, and elemental formula selectively when human milk is unavailable or malabsorption/intolerance persists in older preterm/term infants.
  5. Monitor objectively: daily growth/output review, weekly PN labs, sodium assessment when growth is poor, liver surveillance, and written thresholds for feed advancement or step-back.
  6. Plan beyond the NICU: if PN dependence will persist, start discharge planning at least 4–6 weeks before discharge.

Key Takeaways — Chapter 11.2

  • Intestinal failure is a high-risk malabsorptive state — start a multidisciplinary intestinal rehabilitation plan early, before full enteral nutrition is achievable.
  • Stratify risk on day one (SBS <60 cm, ultra-short <30 cm, surgical NEC, complex gastroschisis, PN >4 weeks) and protect central access from the first PN order.
  • Prevent IFALD: early gut stimulation, human milk, avoid unnecessary fasting, meticulous line care, prompt sepsis treatment, careful lipid/trace-element monitoring.
  • Start feeds early and advance deliberately; don't interpret isolated residuals alone as failure.
  • Replace combined Replogle/ostomy losses with 0.9% NS once output >20 mL/kg/day, escalating reassessment as output rises.
  • Watch sodium stores — low sodium can cause poor growth despite adequate calories.
  • If PN dependence will persist, begin home-PN discharge planning 4–6 weeks ahead with line-care teach-back and a clear fever/line pathway.

References and Evidence Base

  • Baylor College of Medicine. Guidelines for Acute Care of the Neonate, Edition 33, 2025–2026. Section 6.2: Intestinal Failure and Intestinal Rehabilitation.
  • Belize Ministry of Health. Neonatal Clinical Practice Guidelines 2018–2021. Nutritional Support and Necrotising Enterocolitis sections.
  • Lee ES, Kim EK, Shin SH, et al. Efficacy and safety of mucous fistula refeeding in preterm infants: an exploratory randomized controlled trial. BMC Pediatr. 2023;23:137. doi:10.1186/s12887-023-03950-1.
  • MUC-FIRE investigators. MUCous FIstula REfeeding randomized multicenter open-label controlled trial protocol. Contemp Clin Trials Commun. 2023;32:101096. doi:10.1016/j.conctc.2023.101096.
  • American Society for Parenteral and Enteral Nutrition (ASPEN) neonatal nutrition guidance: nutrition support of neonatal patients at risk for NEC and neonatal PN principles.
  • NASPGHAN/ESPGHAN cholestasis guidance for persistent direct/conjugated hyperbilirubinemia and suspected non-IFALD etiologies.